Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
September 24 2024 - 8:00AM
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage
biopharmaceutical company focused on improving patient outcomes
through best-in-class therapies for liver and viral diseases, today
announced the appointment of Dr. Hardean Achneck as Chief Medical
Officer, effective immediately. Dr. Achneck will lead the Company’s
global clinical development efforts and serve as a member of
Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned
clinical development executive with extensive experience across
multiple therapeutic areas, including hepatology and infectious
diseases.
“I am excited to welcome Hardean to Aligos as our Chief Medical
Officer, with expertise across liver indications, including both
MASH and CHB,” said Lawrence Blatt, Ph.D., MBA, Chairman,
President, and Chief Executive Officer of Aligos Therapeutics.
“Following our recent positive topline data for ALG-055009 in MASH
subjects, we look forward to his strategic vision as we progress
towards later stage clinical development with our best-in-class
pipeline of liver and viral therapies.”
“Joining Aligos at this time is a compelling opportunity,
especially after the positive Phase 2a HERALD topline data
readout,” stated Hardean Achneck, MD, Chief Medical Officer at
Aligos. “I look forward to partnering with the team to
strategically lead the Company’s current and future clinical
development with the mission to improve patient outcomes.”
Most recently, Dr. Achneck served as the Senior Vice President
and Head of Clinical Development at Pliant Therapeutics (NASDAQ:
PLRX) where he oversaw all clinical programs, including those in
hepatic diseases. Before joining Pliant, Dr. Achneck was the Vice
President of Clinical Development and Clinical Research at Dicerna
Therapeutics (Nasdaq: DRNA). Following its acquisition by Novo
Nordisk (NYSE: NVO; Nasdaq: Novo-B) in 2021, he continued his role
at the Novo Nordisk Dicerna Transformational Research Unit. He
successfully advanced liver-targeted oligonucleotide assets from
early to late-stage development, notably xalnesiran for chronic
hepatitis B. Prior to his tenure at Dicerna, Dr. Achneck led
Medical Affairs and Clinical Development at Haemonetics Corporation
(NYSE: HAE). Before this, he served as Vice President and Chief
Medical Officer at Hemostemix Inc.
Prior to his industry roles, Dr. Achneck was an Assistant
Professor of Surgery and in Pathology at Duke University School of
Medicine, with a co-appointment as Assistant Professor of
Cardiovascular & Metabolic Disorders at Duke-National
University of Singapore. Dr. Achneck holds an M.D. from Yale
University School of Medicine and a B.A. in Molecular Biophysics
& Biochemistry, magna cum laude, from Yale University. Licensed
to practice medicine in the U.S. and EU, he has authored over 30
peer-reviewed publications and was named an inventor on several
patents.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage
biopharmaceutical company founded with the mission to improve
patient outcomes by developing best-in-class therapies for the
treatment of liver and viral diseases. Aligos applies its science
driven approach and deep R&D expertise to advance its
purpose-built pipeline of therapeutics for metabolic
dysfunction-associated steatohepatitis (MASH) and viruses with high
unmet medical need such as hepatitis B and coronaviruses.
For more information, please visit www.aligos.com or follow us
on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this press release that are not historical
facts may be considered “forward-looking statements,” including
without limitation, statements regarding Aligos’ financial results
and performance as well as research and development activities,
including regulatory status and the timing of announcements and
updates relating to our regulatory filings and clinical trials.
Such forward looking statements are subject to substantial risks
and uncertainties that could cause our development programs, future
results, performance, or achievements to differ materially from
those anticipated in the forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
inherent in the drug development process, including Aligos’
clinical-stage of development, the process of designing and
conducting clinical trials, the regulatory approval processes, and
other matters that could affect the sufficiency of Aligos’ capital
resources to fund operations. For a further description of the
risks and uncertainties that could cause actual results to differ
from those anticipated in these forward-looking statements, as well
as risks relating to the business of Aligos in general, see Aligos’
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on August 6, 2024 and its future periodic
reports to be filed or submitted with the Securities and Exchange
Commission. Except as required by law, Aligos undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances, or to reflect the occurrence
of unanticipated events.
Aligos
Therapeutics
Contact Jordyn TaraziVice President, Investor
Relations & Corporate Communications+1 (650)
910-0427jtarazi@aligos.com
Media ContactInizio EvokeJake RobisonVice
PresidentJake.Robison@inzioevoke.com
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Nov 2023 to Nov 2024